IPO
-
-
-
-
-
-
-
Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
-
-
-
-
-
-
-
Allakos Announces Clinical Update and Third Quarter 2018 Financial Results
-
-
-
-
-
-
-
Allakos Announces Pricing of Initial Public Offering
118,853 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

